In addition to the importance of EGFR at late stages of disease, the activity of ERBB receptors is critical during the early stages of KRAS-driven lung tumours, with the addition of tyrosine kinase inhibitors to MEK inhibition improving survival of a KRas driven murine lung cancer model (Kruspig et al., 2018; Moll et al., 2018). This evidence concerns the gene EGFR and lung cancer.